BofA is Bullish on CRISPR Therapeutics AG (CRSP) [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
On January 22, 2026, TheFly disclosed that Alec Stranahan, a BofA analyst. It reduced the price objective for CRISPR Therapeutics AG (NASDAQ:CRSP) from $90 to $89 and retained a buy rating. Casgevy's 2026 projections were slightly lowered as a result of the modification. Based on an earnings preview paper covering the biotechnology group, BofA still projects consecutive improvement for Casgevy through 2026 despite the change. CRISPR Therapeutics AG (NASDAQ:CRSP) separately announced its planned 2026 milestones and strategic priorities on January 12, 2026. As per the company, Casgevy is gaining traction, and quarterly updates and ongoing worldwide commercialization are anticipated. It is projected that Casgevy regulatory submissions for patients aged 5 to 11 will start in the first half of 2026. According to the firm, additional significant events include the Lp(a) program in 2026 and advancements from CTX310. Furthermore, it includes autoimmune and immuno-oncology updates for zugoc
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Is CRISPR Therapeutics (CRSP) Still Attractive After A 67% Five Year Share Price Decline [Yahoo! Finance]Yahoo! Finance
- Assessing CRISPR Therapeutics' Valuation As Recent Trading Puts CRSP Back In Focus [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics (NASDAQ:CRSP) had its price target lowered by analysts at Bank of America Corporation from $90.00 to $89.00. They now have a "buy" rating on the stock.MarketBeat
- CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors [Yahoo! Finance]Yahoo! Finance
- Crispr Therapeutics: Patience And Opportunity Through Volatility [Seeking Alpha]Seeking Alpha
CRSP
Earnings
- 11/10/25 - Beat
CRSP
Sec Filings
- 1/27/26 - Form 4
- 1/26/26 - Form 4
- 1/22/26 - Form 4
- CRSP's page on the SEC website